Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

trigeminal neuralgia - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

trigeminal neuralgia

MONDO:0008599

Also known as:neuralgia of trigeminal nervetrifacial neuralgiatrifocal neuralgia

Find Clinical TrialsTrials

Overview

Trigeminal neuralgia is a nerve disorder that causes a stabbing or electric-shock-like pain in parts of the face. The pain lasts a few seconds to a few minutes, and usually on only one side of the face. It can also cause muscle spasms in the face the same time as the pain. The pain may result from a blood vessel pressing against the trigeminal nerve (the nerve that carries pain, feeling, and other sensations from the brain to the skin of theface), as a complication of multiple sclerosis, or due to compression of the nerve by a tumor or cyst. In some cases, the cause is unknown. Treatment options include medicines, surgery, and complementary approaches.

GeneticsAutosomal dominant

Treatments1 FDA approved

Clinical Trials48 registered · 21 recruiting

Clinical Presentation

Features include: Trigeminal neuralgia.

Organ System	Phenotype Count	Example Features
Brain and nerves	1	Trigeminal neuralgia

Explore clinical features

Diagnosis

Biomarker and diagnostic research for trigeminal neuralgia has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for trigeminal neuralgia, including CARBAMAZEPINE (EQUETRO, approved 2004). An additional 5 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

48 clinical trials registered, 21 recruiting. Interventions under study include procedural interventions, other interventions, drug therapy, and medical devices. Pipeline includes 2 PHASE4, 1 PHASE3, 4 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06518421](https://clinicaltrials.gov/study/NCT06518421)

Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 1:03 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:190400

Orphanet

European rare disease database

Orphanet:221091

GARD

Genetic and Rare Diseases Info Center

GARD:7805

Questions for Your Care Team

→What are the benefits and potential side effects of EQUETRO for managing trigeminal neuralgia?
→Are any of the 48 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
A potent negative allosteric modulator (NAM) of human alpha5-GABAA receptor	A potent negative allosteric modulator (NAM) of human alpha5-GABAA receptor	Shanghai SIMR Biotechnology Co., Ltd.	2024	—	Designated
carbon dioxide	carbon dioxide	Capnia, Inc.	2015	—	Designated
vixotrigine	vixotrigine	Biogen, Inc.	2013	—	Designated
dehydrated alcohol	dehydrated alcohol	Luitpold Pharmaceuticals, Inc.	2012	—	Designated
L-baclofen	L-baclofen	Osmotica Pharmaceutical Corp.	1998	—	Designated

Research Type	Count	% of Total
Clinical study results	73	26%
Research summaries	71	25%
Laboratory research	59	21%
Patient case studies	28	10%
Disease patterns and progression	27	10%
Testing and diagnosis research	18	6%
New treatment approaches	5	2%
Other research	2	1%

Kisho

trigeminal neuralgia

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Duplication of Right Superior Cerebellar Artery Leading to Trigeminal Neuralgia: A Rare Neurovascular Conflict.

Experience and Efficacy Evaluation of Microvascular Decompression and Selective Nerve Root Dissection in the Treatment of Trigeminal Neuralgia Combined With Glossopharyngeal Neuralgia.

trigeminal neuralgia

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Duplication of Right Superior Cerebellar Artery Leading to Trigeminal Neuralgia: A Rare Neurovascular Conflict.

Experience and Efficacy Evaluation of Microvascular Decompression and Selective Nerve Root Dissection in the Treatment of Trigeminal Neuralgia Combined With Glossopharyngeal Neuralgia.